Gong Yue Chen

US Patent:

20080194522, Aug 14, 2008

Filed:

Aug 25, 2005

Appl. No.:

11/661152

Inventors:

Gong Chen - New York NY, US
Dominic J. Yee - La Jolla CA, US
Niko Gubernator - New York NY, US

International Classification:

A61K 31/404
C07D 491/06
C07D 407/10
C07F 5/02
A61K 31/436
A61P 25/00
A61K 31/69
C12Q 1/26
A61K 31/352

US Classification:

514 64, 549403, 548454, 548405, 546 66, 435 25, 514457, 514414, 514288

Abstract:

The present invention relates to compounds useful for detecting the activity of monoamine oxidases, compounds useful for competitively inhibiting monoamine oxidases, for determining inhibitors of monoamine oxidases and compounds useful for treating monoamine oxidase-related nervous system pathologies, as well as pharmaceutical compositions and methods of manufacture thereof.

US Patent:

20100081786, Apr 1, 2010

Filed:

Apr 11, 2007

Appl. No.:

12/296608

Inventors:

Samuel J. Danishefsky - Englewood NJ, US
J. David Warren - Lodi NJ, US
Jiehao Chen - Fishers IN, US
Bin Wu - Thousand Oaks CA, US
Gong Chen - New York NY, US
Qian Wan - New York NY, US
Zhongping Tan - New York NY, US
Cindy Kan - New York NY, US
Yu Yuan - New York NY, US
Zihao Hua - New York NY, US
Krishnakumar Ranganathan - Oak Park CA, US
John D. Trzupek - New York NY, US

International Classification:

C07K 14/505
C07K 1/00

US Classification:

530322, 530333, 530345

Abstract:

The present invention provides isolated homogeneous polyfunctionalized proteins (e.g., erythropoietin), isolated glycopeptides, and a method for preparing polyfunctionalized peptides and/or proteins via cysteine-free native chemical ligation. In certain embodiments, the invention provides an isolated homogeneous polyfunctionalized protein having the structure (I). In certain other embodiments, the invention provides an isolated glycopeptide having Formula (II). In certain other embodiments, the inventive method is a method for preparing a polyfunctionalized peptide comprising a peptidic backbone made up of four or more amino acids, wherein two or more non-adjacent amino acids are independently substituted with a moiety having the structure (III)-LH. wherein A and L1 are as defined herein.

US Patent:

20170227544, Aug 10, 2017

Filed:

Oct 7, 2015

Appl. No.:

15/502339

Inventors:

- Little Falls NJ, US
Gong Chen - Rutherford NJ, US
Lori Jukofsky - South Plainfield NJ, US
Gwen Nichols - New York NY, US
William E. Pierceall - Madison NJ, US
Bernhard Reis - Basel, CH
Ruediger Rueger - Huglfing, DE
Hua Zhong - Short Hills NJ, US

Assignee:

Hoffmann-La Roche Inc. - Little Falls NJ

International Classification:

G01N 33/574
A61K 45/06
A61K 31/40

Abstract:

The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain MDM2 protein expressing cells and, optionally additional co-variates selected from a gene signature as disclosed herein, p53 mutation status, the patient's age and ECOG score at baseline as a biomarker for predicting said patient's response to treatment.

US Patent:

20170073426, Mar 16, 2017

Filed:

May 8, 2015

Appl. No.:

15/309391

Inventors:

- Tokyo, JP
- Basel, CH
Yasuo SUGITANI - Tokyo, JP
Oscar PUIG - Jersey City NJ, US
Ruey-min LEE - Short Hills NJ, US
Gong CHEN - Rutherford NJ, US
Anton BELOUSOV - Penzberg, DE
Ya-Chi CHEN - Hoboken NJ, US
Bernhard REIS - Basel, CH

Assignee:

Chugai Seiyaku Kabushiki Kaisha - Tokyo
F. Hoffmann-La Roche AG - Basel

International Classification:

C07K 16/30
G01N 33/574
G01N 33/50
C12Q 1/68

Abstract:

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

Author:

Gong Chen

ISBN #:

0757510191

Author:

Gong Chen

ISBN #:

0787243507

Author:

Gong Chen

ISBN #:

0883146576